- Presentations
- 6
- Markets
- 1
Hemlibra is a brand of Emicizumab marketed by Genentech, with 6 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Emicizumab
- Brand owner
- Genentech
- Registered in
- United States
- Strengths and forms
- 105 mg/0.7 mL injection, 12 mg/0.4 mL injection, 150 mg/1 mL injection, 30 mg/1 mL injection, 300 mg/2 mL injection, 60 mg/0.4 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Hemlibra 105 mg/0.7 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Hemlibra 12 mg/0.4 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Hemlibra 150 mg/1 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Hemlibra 30 mg/1 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Hemlibra 300 mg/2 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Hemlibra 60 mg/0.4 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Hemlibra
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.